F2RL2

F2RL2 (PAR3) is a protease-activated G protein-coupled receptor whose N-terminus is cleaved by thrombin to expose a tethered ligand that drives phospholipase C activation and intracellular Ca2+ release; in pancreatic islets this signaling stimulates β-cell exocytosis and insulin secretion, as a thrombin-cleavage-site blocking antibody abolished the response and a tethered-ligand peptide alone was sufficient to trigger exocytosis (PMID:26742564). Beyond this receptor-level mechanism, the available corpus characterizes F2RL2 primarily through its transcriptional and post-transcriptional control: NRF2 binds the F2RL2 promoter and upregulates it in neural progenitor cells in response to lead and arsenic, where F2RL2 loss alters cell death, proliferation, and differentiation (PMID:37939567), and BHMT-dependent DNA methylation regulates its expression in liver (PMID:28179424). Multiple miRNA axes converge on F2RL2 to set its expression level in disease contexts—the NEAT1/miR-582-5p axis (PMID:36540097) and a miR-125b-5p→NFAT2 axis (PMID:37340944) place F2RL2 downstream as a modulator of cardiomyocyte and endothelial apoptosis in myocardial infarction, while miR-5572 directly targets F2RL2 in orbital fibroblasts, with its loss promoting COL1A1-dependent fibrosis (PMID:40750003).

1. 2015 High

   Established the core molecular mechanism of F2RL2 as a thrombin-activated receptor coupled to a functional output, answering how the receptor transduces protease signals into a physiological response.

   Evidence Insulin secretion and single-β-cell capacitance assays in islets with thrombin-cleavage-site blocking antibody, tethered-ligand peptide agonist, and PLC/Ca2+ inhibitors

   PMID:26742564

   Open questions at the time

   • G protein coupling identity not defined
   • No structural data on the receptor or tethered ligand engagement
   • Role outside pancreatic β-cells not addressed
2. 2017 Medium

   Showed that F2rl2 expression is set by DNA methylation, identifying an epigenetic input controlling receptor abundance in liver.

   Evidence RRBS methylome plus RNA-seq in Bhmt-null vs wild-type mouse liver across four time points

   PMID:28179424

   Open questions at the time

   • Functional consequence of F2rl2 underexpression not tested
   • Causality between specific CpG methylation and transcription not directly demonstrated
   • Relevance to human F2RL2 unknown
3. 2022 Medium

   Defined F2RL2 as a downstream effector of an lncRNA/miRNA axis controlling cardiomyocyte survival, framing it as a pro-apoptotic node in myocardial infarction.

   Evidence Dual-luciferase miR-582-5p/F2RL2 reporter, NEAT1 silencing epistasis, MI mouse model and OGD cardiomyocyte assays

   PMID:36540097

   Open questions at the time

   • Receptor-level signaling mechanism in cardiomyocytes not dissected
   • Single-lab study
   • Endogenous ligand driving F2RL2 in ischemia not identified
4. 2022 Low

   Provided protein-level localization and a candidate disease variant, placing F2RL2 in retinal cell types relevant to macular disease.

   Evidence Immunohistochemistry in human and pig retina plus genetic association of F2RL2 p.Leu289Arg in maculopathy families

   PMID:36275200

   Open questions at the time

   • Functional consequence of the variant not tested
   • Causal role in AMD progression not established
   • IHC localization not corroborated by functional assay
5. 2023 Medium

   Identified NRF2 as a direct transcriptional activator of F2RL2 linking xenobiotic/oxidative stress to receptor expression and neural progenitor fate.

   Evidence ChIP-qPCR for NRF2 binding to F2RL2 promoter plus siRNA knockdown with viability, proliferation and differentiation readouts in NPCs

   PMID:37939567

   Open questions at the time

   • Downstream signaling connecting F2RL2 to fate decisions undefined
   • Single-lab study
   • Whether receptor activity or expression level drives the phenotype unclear
6. 2023 Medium

   Resolved an indirect miRNA route to F2RL2 via the transcription factor NFAT2, ordering a regulatory axis affecting endothelial survival in ischemia.

   Evidence miR-125b-5p mimic/inhibitor, NFAT2 overexpression and F2RL2 siDNA rescue experiments in OGD endothelial cells and MI mouse model

   PMID:37340944

   Open questions at the time

   • Direct NFAT2 binding to F2RL2 promoter not shown
   • Receptor signaling mechanism not addressed
   • Single-lab study
7. 2023 Low

   Tested whether F2RL2 participates in protease-driven airway inflammation, but left its individual contribution unresolved.

   Evidence Calcium mobilization assay with purified chicken trypsin II-P29; functional knockdown used F2R and F2RL1 rather than F2RL2

   PMID:37253661

   Open questions at the time

   • F2RL2-specific knockdown not performed
   • Direct cleavage of F2RL2 by the protease not demonstrated
   • Individual contribution to inflammation not isolated
8. 2023 Low

   Implicated F2RL2 among GPCRs promoting osteogenic differentiation, but as part of a receptor class rather than individually validated.

   Evidence In vitro GPCR screen for biomineralization with transcriptome/ATAC-seq and in vivo bone/pulp models

   PMID:38100905

   Open questions at the time

   • No F2RL2-specific knockdown or mutagenesis
   • Downstream p53 pathway attributed to the class not F2RL2
   • Ligand and signaling in this context undefined
9. 2025 Medium

   Showed direct miRNA targeting of F2RL2 controls a fibrotic output, linking receptor expression to collagen production in orbital fibroblasts.

   Evidence Dual-luciferase miR-5572/F2RL2 reporter, miR-5572 inhibitor transfection, qRT-PCR and western blot for F2RL2 and COL1A1

   PMID:40750003

   Open questions at the time

   • Mechanism linking F2RL2 to COL1A1 not dissected
   • Receptor signaling vs expression role unclear
   • Single-lab study in one cell type

• How F2RL2's thrombin-activated receptor signaling mechanistically connects to its diverse disease phenotypes (cardiac apoptosis, fibrosis, neural differentiation, macular disease) remains unresolved, as does its G protein coupling and endogenous activating proteases across these tissues.
• No structural model of receptor or tethered-ligand engagement
• G protein/effector coupling beyond PLC/Ca2+ undefined
• Mechanistic link between expression-level regulation and downstream phenotypes unestablished